Human peripheral blood mononuclear cells and T-cell lines and clones from individuals immunized with rabies PM vaccine were tested for the ability to recognize antigenic determinants in rabies and rabies-related viruses in an antigen-induced proliferation assay. Some, but not all, of the T cells from these individuals cross-reacted with various laboratory strains of rabies virus and with rabies-related viruses such as Duvenhage and Mokola. In addition, these T cells were shown to react with epitopes of either the ribonucleoprotein or the viral glycoprotein. Rabies-specific cytotoxic T-cell responses by a CD4+ T-cell line were evident against antigenic determinants of the ribonucleoprotein and glycoprotein.
The rapid appearance of high and long-lasting virusneutralizing antibody (VNA) titers in rabies virus vaccine recipients has been correlated with the efficacy of the vaccine (5, 25) . In humans, rabies vaccine is administered to individuals at high risk of infection, such as research workers and veterinarians (pre-exposure treatment), or to people exposed to a rabies-infected animal (postexposure treatment). However, concern exists as to the protective value of the rabies vaccines currently used in humans against the antigenically distinct rabies virus variants (e.g., Duvenhage and Mokola) (6, 14, 16, 22, 32) . Recently, reported failures in postexposure treatment for rabies (15, 24) might be attributed to antigenic differences between field virus strains and the strains used for vaccine production.
As with most antibody responses, the production of rabies-specific VNA is likely to depend on the participation of helper T lymphocytes (Th). In a typical immune response, Th must deliver appropriate signals to antigen-stimulated B lymphocytes for optimal synthesis of antibodies. Some of these helper signals are in the form of soluble factors (lymphokines) produced and secreted by the T cells upon antigen stimulation (10) . Thus, the recognition of viral antigens by Th is probably a crucial event for the protective immune response to rabies virus. In addition to Th, other T cells such as cytotoxic T lymphocytes (CTL) may contribute in preventing rabies virus infection and spread throughout the nervous system (29, 31) .
Unlike B lymphocytes, T cells do not react with soluble antigen but do recognize antigen on the surface of an accessory cell known as antigen-presenting cell (APC) or a virus-infected cell (target cell). Studies in various laboratories have revealed that T lymphocytes recognize determinants contained within relatively small amino acid sequences of antigen (9, 11, 27) . Most of the results also indicate that T cells react with epitopes that arise from the interaction of these amino acid sequences of antigen with surface molecules encoded by the major histocompatibility gene complex (MHC) which are expressed on the APC or target cell surface (2, 13, 20, 27, 28) . In humans, the MHC-derived elements that restrict the response of Th to antigen, known as class II molecules, are products of the HLA-DR, HLA-DP, and HLA-DQ genes. In addition, there are some reports of class II MHC-restricted CTL (12, 17, 35 (36) .
Our previous studies have demonstrated antigen-specific T-cell responses in human recipients of rabies vaccine (4). Antigen-specific T-cell lines (and clones) were derived from the peripheral blood of rabies vaccinees by multiple stimulation treatments with inactivated rabies virus in the presence of irradiated autologous APC and interleukin-2 (IL-2). Cell surface phenotype analysis revealed that most of these rabies-specific lymphocytes belonged to the CD4+ (helper/ inducer) class of T cells. These T-cell lines proliferated and produced gamma interferon when stimulated with rabies antigens in the presence of autologous or histocompatible APC (4).
We report here our studies of the reactivity of various T-cell clones to different strains of rabies and rabies-related viruses, results of experiments to identify the viral molecules which are recognized by these T cells, and our analysis to measure rabies-specific cytotoxic activity by CD4+ T cells from human vaccine recipients.
MATERIALS AND METHODS
Viruses and antigens. Rabies virus strains PM, CVS, ERA, PV, North American bat (NAB; strain 6014), and Polish bat Duvenhage 6 (DUV6) and Mokola-3 virus were purified by gradient centrifugation from culture supernatants of baby hamster kidney cells infected with these viruses as described previously (30) . After purification, these viruses were inactivated with P-propiolactone. Ribonucleoprotein (RNP) from PM rabies virus was purified from lysates of infected cells as described before (21) . Purified RNP was shown to be free of viral glycoprotein by gel electrophoresis and immunoassays. Rabies glycoprotein (G) was purified from PM virus by isoelectric focusing (7) . A vaccinia recombinant virus (V-RG) which expresses the rabies viral glycoprotein of strain ERA (33) was used to infect both APC and target cells at a multiplicity of 10 PFU/cell.
Rabies virus-reactive T lymphocytes. Healthy individuals (male and female adults) who received the pre-exposure treatment with rabies vaccine of the PM strain (Imovax; Merieux Institute, Miami, Fla.) were chosen for the present study. VNA titers in the sera of these individuals were determined as described before (19 " Virus neutralizing activity of serial dilutions of sera obtalined 7 days after the last (third) immunization with rabies vaccine was measured as described in Materials and Methods.
" Std is international reference standard serum containing 2 IU of VNA activity per ml.
Numbers in italics represent no significant VNA activity as compiared with normal nonimmune human serum.
RESULTS
Humoral and cellular immune responses to various rabies and rabies-related viruses in human vaccine recipients. Serum and PBMC from five healthy rabies vaccine recipients were obtained 7 days after the last immunization. VNA titers and cell-proliferative responses to various viruses were measured. All five individuals had VNA to PM, CVS, ERA, and NAB, and all of these titers were higher than the international reference standard serum of 2 IU/ml ( Table 1) . Sera of three of the vaccinees (WI-3, WI-4, and WI-5) also exhibited VNA to the Polish bat virus DUV6. None of the individuals appeared to have VNA specific for Mokola virus.
The PBMC from all five vaccine recipients showed a significant proliferative response to purified and inactivated rabies viruses PM, PV, CVS, ERA, and NAB and to the rabies-related viruses DUV6 and Mokola ( 6 (B6, B7, C2, C7, C14, and C18) proliferated in response to both PM and CVS viruses, 9 recognized PM, CVS, and ERA viruses, 2 (Al and C10) reacted with PM, CVS, ERA, and DUV6, and 4 (B3, B4, B5, and C9) were triggered to proliferate by Mokola and DUV6 viruses in addition to all other rabies virus strains tested (Table 3 ).
The T-cell clones were tested for their reactivity with either purified RNP from PM virus or V-RG-infected APC. Of 22 clones tested, 8 proliferated well to in response to RNP, 6 recognized the V-RG-infected APC, and, 8 failed to recognize either RNP or V-RG ( "Calculated from triplicate samples as described in Materials and Methods. Those of >3 represent significant proliferation.
b V, Purified inactivated virus tested at 5 ,ug/ml.
'Purified RNP tested at 5 ,ug/ml.
( Table 5 ). Furthermore, two clones (Al and B3) which had previously been demonstrated to react with RNP (Table 4) failed to exhibit a proliferative response to this preparation of G protein ( Table 5 ). The remaining clone (B4) reacted only to whole virus and failed to recognize G protein.
Cytotoxic responses of rabies-reactive T lymphocytes. A CD4+ long-term cultured T-cell line derived from a different rabies vaccine recipient (WI-7) was studied for its ability to kill cells that present rabies antigens. EBV-transformed lymphoblastoid cells from the same vaccine recipient were either infected with V-RG or incubated with rabies antigens and used as targets in a 4-h cytotoxic 51Cr release assay. The V-RG-infected autologous targets were readily lysed by the T-cell line, as were target cells previously incubated with either purified PM rabies virus or RNP (Fig. 1) 
obtained with T-cell lines isolated from other vaccine recipients (data not shown).
To determine whether the lytic effect of rabies-specific T cells required cell-to-cell contact with the target cells, antigen-minus, 51Cr-labeled target cells (bystander cells) were mixed at a 1:1 ratio with unlabeled target cells incubated previously with rabies antigens, and the percent cytotoxicity was determined 4 h after the addition of the rabies-specific T cells. No killing of bystander target cells occurred under these circumstances; only the 51Cr-labeled target cells infected with V-RG (Fig. 2) or incubated with RNP ( Fig. 3) were killed.
The cytolytic activity of the rabies-specific CD4+ T-cell line was tested with V-RG-infected target cells from MHCtyped individuals. A high degree of cytotoxicity was observed against the target cells that shared with the T-cell line at least one of the MHC class II determinants (Fig. 4) . On the Table 4 ).
other hand, HLA-DR-mismatched target cells were much less susceptible to lysis by the T cells (Fig. 4) . Uninfected target cells from all three individuals were not killed by the effector T cells (data not shown). DISCUSSION Although the immune mechanisms responsible for resistance to rabies virus infection are not fully understood, the presence of rabies-specific VNA after vaccination has been reported to correlate with survival to rabies infection (5). However, as we have recently reported (6) examples in which no direct correlation exists between levels of VNA and survival after rabies infection. In experiments presented here, all five recipients of rabies PM vaccine produced significant VNA to PM, ERA, CVS, and NAB viruses, and three of these individuals also had significant VNA titers to the Polish bat strain DUV6. None of the five vaccinees had VNA to Mokola virus.
In addition to VNA, other immune mechanisms might play an important role in rabies immune responses. There is ample evidence indicating that cellular immune responses could be critical in postexposure treatment of rabies (29, 31) . In our study, PBMC from all five vaccinees recognized viral antigens present in all rabies and rabies-related strains tested as indicated in the lymphocyte proliferation assays. Furthermore, lymphocytes from the two vaccine recipients who lacked VNA to DUV6 virus (WI-1 and WI-2) showed proliferative responses to DUV6 that were indistinguishable from Fig. 1 to 3. those of the three vaccinees with VNA to this virus. From the same results, it also appears that many of the crossreactive determinants recognized by the T lymphocytes of human vaccine recipients are present in the RNP of the viruses; however, it is possible that cross-reactive T-cell epitopes also exist in the other viral components. The lack of correlation between the VNA and cellular immune responses to DUV6 and Mokola viruses in the human vaccine recipients could reflect, in part, the presence of few crossreactive determinants for antibodies between these viruses and the PM vaccine virus strain.
T-cell clones derived from a rabies vaccine recipient were analyzed for their specificity for various viruses and their reactivity with purified RNP from PM virus and to V-RGinfected APC. Two of these clones (Bi and C16) were highly specific for the immunizing virus (PM), since they did not respond to any of the other viruses, but neither reacted with RNP (from PM) or, as expected (see below), with V-RGinfected APC (Table 4) . Only one (B6) of the six T-cell clones that recognized both PM and CVS viruses showed specificity for antigenic determinants present in the viral RNP. Since the rabies G protein expressed by V-RG is derived from ERA virus (33) (23) . Furthermore, we have recently reported that immunization with purified rabies RNP failed to induce VNA but protected the animals against a peripheral viral challenge (8) . One explanation for these findings is that, although no detectable VNA exist in the immune animal at the time of virus challenge, the presence of Th facilitates the rapid immune response to the antigens present in the viral challenge, resulting in the production of VNA. Thus, under these circumstances, the viral challenge could act as a booster immunization inducing an anamnestic antibody response. Viewed in this light, the presence in rabies immune humans of Th able to cross-react with viruses such as DUV6 and Mokola could indicate that these individuals are protected against these viruses, even in the absence of VNA.
